Limited proteolysis of most large protein precursors is carried out in vivo by the subtilisin-like pro-protein convertases. Many important biological processes such as peptide hormone synthesis, viral protein processing and receptor maturation involve proteolytic processing by these enzymes, making them potential targets for the development of novel therapeutic agents. However, the efficient development of such molecules requires a better understanding of the molecular mechanisms of proteolytic protein processing. Herein, we review the most recent findings on the molecular aspects of subtilisin-like convertase activity, such as the structural analysis of the proteases, the mechanisms of enzyme/substrate specificity, their interaction with other proteins such as 7B2, and the comparative tissue and cellular distribution of the enzymes and their substrates. These data are then used as a background for the review of the known biological functions of subtilisin-like pro-protein convertases, the reported clinical cases involving proteolytic processing defects and, finally, the ongoing development of new therapeutic inhibitor molecules based on this knowledge.
INTRODUCTION
Proteolytic processing is a post-translational modification by which the cell can diversify and regulate the products of its genes. Just as a single polycistronic bacterial gene can encode many proteins with different functions, a mammalian precursor protein can give rise, by hydrolysis of selective peptide bonds, to several molecules with different biological activities. Proteolytic processing within the secretory pathway is crucial for the activation or inactivation of many proteins and the regulation of their cellular localization. Indeed, processing is important in zymogen activation, peptide hormone processing, complement activation, clot formation and lysis, angiogenesis and tissue remodeling. Many precursors involved in these important biological functions require cleavage at specific pairs of basic residues, such a Lys-Arg. In mammalian species, this catalytic function is now understood to be carried out by a family of subtilisin-related pro-protein convertases, known as the SPCs.
The discovery of the SPCs was based on initial observations made in the mid-80s using yeast genetics. A mutation in the Kex2 gene in Saccharomyces cerevisiae prevented conjugation because it did not permit proteolytic processing of the alpha-mating factor precursor. Genetic complementation with Kex2 revealed a deficiency in the expression of a peptidase with specificity for cleaving on the carboxyl (C) side of paired basic residues (Julius et al. 1984) . The Kex2 peptidase, now known as kexin, is a serine protease of the subtilisin family (Wells et al. 1983 , Mizuno et al. 1988 ) that has been shown to be calcium-dependent (Fuller et al. 1989a , Mizuno et al. 1989 and to cleave correctly the pro-hormone precursors in mammalian cells (Thomas et al. 1988) . It was thus logical to assume that a mammalian homolog could exist. Shortly after the discovery of the yeast enzyme, a sequence homology analysis (Fuller et al. 1989b ) through the human genome database identified a mammalian Kex2 homolog that was encoded by the fur gene, on chromosome 15 (van den Ouweland et al. 1989 (van den Ouweland et al. , 1990 . Subsequently, seven kexin-related mammalian enzymes were identified. Although each enzyme has been independently named by its discoverers, a simplified nomenclature for the group of mammalian processing proteases has been proposed (Chan et al. 1992) , using the term SPC: SPC1 (furin or paired amino acid converting enzyme (PACE)), SPC2 (PC2), SPC3 (PC1 or PC3), SPC4 (PACE4), SPC5 (PC4) SPC6 (PC5 or PC6-A) and SPC7 (LPC, PC7 or PC8) .
The large number of mammalian SPCs now discovered raises several intriguing questions as to their potential overlapping or distinct functions. Functional specificity could be determined by 1) a high degree of substrate specificity by each enzyme, and 2) a distinct cellular expression or specific intracellular localization of each SPC. The future development and successful application of SPC inhibitors as potential therapeutic agents is highly dependent on the availablility of this information. Within the context of the intracellular environment, will SPC inhibitors have to be designed that target all SPC activities simultaneously, or will inhibitors that target specific SPC activities be more effective? Thus the knowledge gained from defining whether SPCs have redundant or distinct functions, at the level either of expression or of activity, will be extremely useful. One approach to this problem is to define the cellular localization of SPCs -that is, to identify precisely the 'cocktail' of SPCs expressed in any cell of interest. Indeed, this is an important criterion, as the specificity of processing function is not only dictated by the cleavage specificity of an SPC, but also by its distinct localization. A second approach is to define better the cleavage specificity of each SPC and to define how SPCs are regulated, for example at different levels including transcriptional, translational, and through protein-protein interactions (e.g. SPC2/7B2, see later). Finally, the ability to 'delete' a specific SPC from the cellular environment, such as has been accomplished with the creation of null mice, is especially useful to define the unique functions of that SPC and the possible compensatory contributions of other co-localized SPCs.
MECHANISM OF SPC PRO-PROTEIN PROCESSING
In general, SPCs appear to be highly specific enzymes, cleaving pro-protein precursors at specific positively charged amino acids, usually to produce biologically active products. Other serine proteases, such as trypsin or chymotrypsin, are far less selective, often playing a role in protein degradation. Peptide processing events occur in the secretory pathway of eukaryotes at the carboxyl terminal of Lys or Arg residues (occupying the P1 position). (The cleavage site of proteases is described according to a nomenclature proposed by Schechter & Berger (1967) , whereby P1 is the first residue on the amino (N)-terminal side of the cleaved peptide bond, P2 the second residue, and so on. The amino acids located on the C-terminal side of the cleavage site are named P1 , P2 , P3 , etc.) Typically, SPC cleavage sites feature Arg-Arg and Lys-Arg motifs, but some are composed of Arg-Lys, Lys-Lys, or even single Arg residues.
The substrate specificity of SPC1 has been the object of numerous studies and is the best understood, revealing the consensus recognition sequence Arg-Xaa-Arg/Lys-Arg?, of which the P4 arginine is critical for cleavage (Hosaka et al. 1991 , Molloy et al. 1999 . Analysis of a repertoire of more than 40 precursor molecules cleaved at furin sites also showed that 50% of the pro-proteins possessed a serine residue in the P1 position. The mimimal recognition sequence, Arg-Xaa-Xaa-Arg?, is observed in all substrates found to be cleaved by SPC1. This sequence was later confirmed in studies using random substrate phage display. In these experiments, virtually all clones coding for SPC1 substrates had an RxxR? motif, and many had Lys, Arg, or Pro in the P2 position (Matthews et al. 1994a) . The presence of a P4 Arg residue is not mandatory for the activity of all convertases but, generally, the presence of an Arg residue in P6, P4 or P2 has been shown to enhance the cleavage efficiency by SPCs (Hosaka et al. 1991) .
The general features of intracellular precursor processing are shown schematically in Fig. 1 . Precursor processing can occur in both the constitutive and the regulated pathways. It is believed that SPC1 is important in the cleavage of precursors in the constitutive pathway, whereas SPC2 and SPC3 are important in the cleavage of precursors in the regulated pathway. After SPC cleavage, the newly exposed basic residues of the released N-terminal peptide are removed by carboxypeptidases specific for basic residues (Kemmler et al. 1973) . Recently, it has been shown that this role can be carried out, not only by carboxypeptidase E (CPE), but also by a structural homolog known as carboxypeptidase D (CPD) (Xin et al. 1997) . CPE has been shown to be targeted to secretory granules and appears to play this role in a relatively endocrine-specific manner (Fricker 1991).
In contrast, CPD appears to have a role in processing of proteins negotiating the constitutive secretory pathway (Dong et al. 1999) . Finally, after removal of the basic residues, peptides having a C-terminal glycine are often amidated by the action of peptidyl-glycine--amidating mono-oxygenase. This modification enhances the binding of neuroendocrine peptides to their receptor and increases peptide stability in vivo (Mains et al. 1990) .
Interestingly, the steps of this enzymatic cascade involving the SPCs and carboxypeptidases appear to be functionally linked. It has been observed that carboxypeptidase activity enhances SPC2 processing of pro-dynorphin, suggesting that the removal of C-terminal basic residues prevents product inhibition (Day et al. 1998) . Hence, CPE activity could play a regulatory role on SPC activity in vivo. This notion is supported by studies on CPE-null mice (fat/fat), which show generally reduced SPC processing activity that could be due to the accumulation of C-terminally extended peptides (Naggert et al. 1995) .
STRUCTURAL ANALYSIS OF SPC ENZYMES
Substrate specificity, catalytic efficiency and intracellular localization of each SPC are conferred by the unique structural components of each molecule. All the members of this enzymatic family have similar N-terminal structures with common functional domains, whereas their C-terminal domains are variable. The more conserved N-terminal domains are the signal peptide, the pro-segment, the catalytic domain and the P domain, which includes a conserved RGD motif (Fig. 2) . The more variable C-terminal domains include Cys-rich regions, transmembrane and cytosolic domains, amphipathic helices, and sorting domains. Like other protein precursors, SPCs are first synthesized as large inactive pro-proteins that undergo proteolytic maturation in their transit through the secretory pathway. The first domain to be removed is the N-terminal signal peptide that is required for the entry of the protein into the secretory pathway. This peptide is cleaved by a signal peptidase after the translocation of the nascent polypeptide chain through the endoplasmic reticulum (ER) membrane. The second processing event is the removal of the 80-90 amino acid pro-segment. This domain has two important functions: as an intramolecular chaperone and as a competitive inhibitor. Study of the bacterial subtilisin model and other pro-proteins suggests that N-terminal pro-peptides act as intramolecular chaperones and are essential for proper folding of the proteins to which they are attached (Eder et al. 1993 , Shinde & Inouye 1993 . It has been demonstrated that these pro-peptides are cleaved by an intramolecular autocatalytic mechanism at the ER level (Leduc et al. 1992 , Creemers et al. 1993b , Goodman & Gorman 1994 , Matthews et al. 1994b , Lamango et al. 1999 , and this cleavage is important for the correct sorting of the enzymes out of the ER (Creemers et al. 1995 , Zhou et al. 1995 . Two clusters of pairs of basic residues are found in the pro-segment of each convertase. The excision of the pro-peptide in the ER occurs at the C-terminal site, for which the consensus sequence is Arg-Xaa-Arg/ Lys-Arg?. After this first cleavage, the pro-segment most probably occupies the active site, acting as a competitive inhibitor until it is released. In the case of SPC1, a correct calcium and pH environment found in the trans-Golgi network (TGN) enables cleavage at the N-terminally located pair of basic residues of the pro-peptide, thus releasing it from the catalytic domain and activating the enzyme (Anderson et al. 1997) . Purified SPC3 pro-peptides have been shown to inhibit SPC3 and SPC1 activity in vitro (Boudreault et al. 1998) , thus confirming the role of the pro-peptide regulatory mechanism of SPC activity. It is likely that this two-step pro-segment processing is a common feature of all SPCs. In most cases (with the exception of SPC2), the first cleavage is an early event that is necessary for the efficient folding and the sorting of the protease in its appropriate cell compartment. The second cleavage occurs later, when the enzyme has reached its target compartment, where optimal conditions of pH, Ca 2+ concentration and interactions with other proteins are found. The necessity of a second cleavage for pro-peptide release insures that the enzyme becomes activated only after reaching its target cellular compartment.
The catalytic domain contains the active site of the enzyme, with the typical catalytic triad of subtilisin-related serine proteases, including the Asp, His and Ser active site residues. SPCs use the same enzymatic mechanism (i.e. the same catalytic triad) as the trypsin-related enzymes, although no sequence homologies exist between these two families. Hence, SPCs are believed to have arisen from a convergent evolutionary mechanism. Understanding the conformation of the catalytic domain of SPCs is important, because this structure is primarily responsible for substrate selectivity. Although efforts are in progress to obtain threedimensional structures of SPCs, the only catalytic domain model available at present is based on the structure of bacterial subtilisin (Siezen et al. 1994 , Lipkind et al. 1995 . Furthermore, various residues that play a role in the substrate recognition of SPCs have been identified by mutational analysis confirming that negatively charged residues of the catalytic pocket interact with positively charged residues of the substrate (Creemers et al. 1993b , Rockwell & Fuller 1998 . Interestingly, SPC active site residues can be engineered to modify substrate specificity (Rheinnecker et al. 1993) , as is the case, for example with furilisin (Ballinger et al. 1996) , a bacterial subtilisin mutant that has been re-designed to induce a substrate recognition similar to that of mammalian SPC1. The active site of SPCs also contains a conserved Asn residue needed for the stabilization of the oxyanion hole transiently formed during the hydrolysis reaction. Curiously, SPC2 differs from the other SPCs, as the Asn residue is replaced by an Asp. The significance of this special feature of SPC2 is not clear, as an Asp<Gln mutation at this residue has been reported to produce minor effects on SPC2 activation and processing activity (Zhou et al. 1995) . Other studies report that the Asp residue could be involved in the characteristic slow activation of SPC2 and its acidic pH optimum .
The P domain (also called HomoB domain) is located C-terminally to the catalytic region of all SPCs and is essential for the correct folding and the stability of the enzyme. As the ternary structure of SPCs is not yet understood, the exact conformation of this particular domain remains hypothetical. However, it has been proposed, on the basis of secondary structure predictions, that the P domain is an independently folded component consisting of eight-stranded beta-barrels with well-organized inner hydrophobic cores . This compact subunit is believed to be essential for the structural cohesion of SPCs, by establishing strong hydrophobic interactions with the catalytic domain. Mutational analysis and chimeric constructions in the P domain of SPC3 demonstrate the importance of this region in regulating the stability, calcium dependence, and optimal pH of these enzymes . The importance of this domain for the structural cohesion of the enzyme is also demonstrated in human colon carcinoma LoVo cells, in which a single nucleotide deletion in the region covering the P domain of SPC1 completely abolishes its activity (Takahashi et al. 1993 (Takahashi et al. , 1995b .
The P domain of SPCs also contains a conserved RGD motif, the role of which remains unclear. RGD motifs are typically found in extracellular matrix proteins, such as fibrinogen, and are involved in cellular adhesion via integrins. However, there is at present no evidence that the RGD motif in SPCs is involved with integrin attachment, either intracellularly or extracellularly , Rovere et al. 1999 . Mutational analysis of the RGD motif in SPC3 produces confusing results, with effects on substrate processing (proopiomelanocortin, POMC), precursor processing (pro-segment removal and C-terminal cleavage), enzyme stability and intracellular sorting (Lusson et al. 1997) . From these same studies, it also appears that modification of the P domain (i.e., within the RGD motif) probably results in a structural destabilization that could explain all other effects observed. Other experiments with kexin P domain mutants support the notion that such modifications can have drastic effects on enzyme trafficking, resulting in a failure to exit from the ER (Gluschankof & Fuller 1994) .
The regions located C-terminal to the P domain are highly variable for each convertase. For example, cysteine-rich regions are found in SPC1 (van de Ven et al. 1990 ), SPC4 (Kiefer et al. 1991) , and SPC6 (Lusson et al. 1993) . The isoform of SPC6, known as SPC6-B (see Fig. 2 ) has a particularly extended Cys-rich region. Interestingly, this domain has some homology with receptor protein tyrosine kinase precursors. However, few studies have examined the role of this domain, which remains unknown. In contrast, the C-terminal domain of SPC7 displays a unique serine/threonine-rich region of unknown function (Bruzzaniti et al. 1996 , Meerabux et al. 1996 , Seidah et al. 1996c , reminiscent of the yeast Kex2 enzyme.
Other regions in the C-terminal part of SPCs have been identified for which the functions are better understood, such as those regions that interact with lipidic membranes. Some SPCs (SPC1, SPC7 and the variant isoforms, SPC4E and SPC6B) have an integral transmembrane domain followed by a cytoplasmic tail. This domain affects cellular sorting and has been well studied for SPC1 (Molloy et al. 1999) . As a constitutive pathwayassociated protease, SPC1 is a resident TGN protein (Shapiro et al. 1997 ) that can enter a recycling pathway through the plasma membrane and the endosomes (Molloy et al. 1994 ). This particular sorting pattern is made possible by its transmembrane domain and the interactions of its C-terminal tail with cytoplasmic proteins. An acidic amino acid cluster important for cell sorting has been identified within the SPC1 56 amino acid cytosolic domain (Schafer et al. 1995) . This motif contains phosphorylated serine residues (Takahashi et al. 1995a ) that regulate the SPC1 intracellular traffic by casein kinase II (Jones et al. 1995) . Dephosphorylation is carried out by PP2A phosphatase . When phosphorylated, the SPC1 cytoplasmic tail interacts with phosphofurin acidic cluster sorting protein 1, a novel sorting protein related to clathrin-associated molecules (Wan et al. 1998) . Other important cytoplasmic tail sorting signals have been identified, namely a tyrosine-based motif important for the interaction with AP-1 Golgi-specific assembly proteins (Teuchert et al. 1999) and, recently, hydrophobic based motifs that could mediate internalization (Stroh et al. 1999) .
Other SPCs, such as SPC3 and SPC2, do not have an integral membrane domain, but are believed to have an amphiphatic helix that has been hypothesized to mediate hydrophobic interactions with membranes (Seidah et al. 1990 ). However, an SPC2 deletion mutant lacking the putative C-terminal amphipathic helix was nevertheless membrane associated, suggesting that this domain was not essential for attachment of SPC2 to membranes (Shennan et al. 1991) .
A COMPLEX CASE: SPC2 BIOSYNTHESIS
As for other SPCs, during its biosynthesis, SPC2 proceeds through a series of intermediate forms (Guest et al. 1992 , Lamango et al. 1999 . After pro-peptide removal by an autocatalytic mechanism (Matthews et al. 1994b ), the enzyme is further processed by a truncation of its C-terminal domain and glycosylation to yield a final product of 64 kDa SPC2 (Shen et al. 1993) . It is noteworthy that SPC2 and SPC3 pro-segment removal occurs at different pH and calcium requirements, suggesting different intracellular locations for these events (Shennan et al. 1995) . Finally, SPC2 is sorted to the regulated secretory pathway (Guest et al. 1992 , where it fulfills its role in the production of bioactive peptide hormones.
The biosynthesis of active SPC2 is tightly linked to the expression of the neuroendocrine polypeptide, 7B2 (Jeannotte et al. 1997 , Seidel et al. 1998 . This protein was first isolated from pituitary extracts (Hsi et al. 1982 , Seidah et al. 1983 ) and its cDNA was later cloned (Martens 1988 , Mbikay et al. 1989 . It is a sulfated, non-glycosylated peptide (Ayoubi et al. 1990 , Paquet et al. 1994 ) with a strictly neuroendocrine distribution. 7B2 expression is required for the efficient transport, folding and activation of SPC2 (Braks & Martens 1994 , Martens et al. 1994 , Zhu & Lindberg 1995 , Lamango et al. 1996 . The two molecules are bound together at their entry in the ER and are later cleaved by an SPC1-like activity (Paquet et al. 1994) in their transport through the secretory pathway (Braks & Martens 1994 ). The SPC2 pro-segment is required, but is not sufficient to confer 7B2 binding (Zhu et al. 1998) , and the interactions between these molecules have been used to explain the relatively slow exit of SPC2 from the ER (Muller et al. 1997) .
7B2 is considered to be a bifunctional molecule, with its N-terminal domain behaving as a chaperone-like protein, while its C-terminal peptide domain is a specific SPC2 inhibitor (Martens et al. 1994 , Zhu & Lindberg 1995 having no effect on SPC3 activity (van Horssen et al. 1995) . This C-terminal region appears not to be responsible for the observed binding of pro-7B2 with pro-SPC2 in the ER. A working model of 7B2 and SPC2 interactions based on these results is summarized in Fig. 3 .
In vivo studies have attempted to establish the role of 7B2. Whereas 7B2 and SPC2 are clearly co-localized in rat brain neurons, 7B2 has also been shown to be more widely distributed than SPC2 (Seidel et al. 1998) , with many 7B2-positive neurons showing a lack of SPC2 expression. What is the function of 7B2 in these SPC2-negative neurons? It remains to be established whether 7B2 specifically binds another protein, maybe even an 'SPC2-like' molecule, in these neurons. These potential additional functions of 7B2 have been highlighted by recent gene knockout experiments (Westphal et al. 1999) . Although gene disruption of 7B2  3. Hypothetical model of 7B2 and SPC2 interactions. (A) Shortly after biosynthesis, pro-SPC2 (75 kDa) specifically associates with pro-7B2 (27 kDa) within the ER. (B) The complex exits from the ER and, within the TGN, SPC1 (scissors) cleaves the C-terminal (C-T) peptide from pro-7B2 and also cleaves pro-SPC2 (75 kDa to 71 kDa form). (C) By an as yet unexplained mechanism, the 21 kDa 7B2 facilitates the conversion of pro-SPC2 to fully active SPC2 (68 kDa form). (D) The C-T peptide inhibits the activity of SPC2 in late compartments (TGN or immature secretory granules). Inhibition of SPC2 (68 kDa form) is released by cleavage of the C-T peptide by SPC2 at KK residues (and after C-terminal basic residue trimming by carboxypeptidases).
prevents activation of SPC2, other important effects have been observed. 7B2-null mice display hypoglycemia, hyperproinsulinemia, and hypoglucagonemia. They also have increased circulating adrenocorticotrophic hormone (ACTH) and corticosterone concentrations, with adrenocortical expansion. 7B2-null mice do not survive more than 9 weeks, because of severe Cushing's syndrome. In these mice, pituitary intermediate lobe ACTH hypersecretion results in a far more severe endocrine disorder than is found in the SPC2-null mice (Furuta et al. 1997 ). Thus it is highly likely that 7B2 has functions additional to that of activating SPC2.
TISSUE DISTRIBUTION AND CELLULAR LOCALIZATION OF SPC ENZYMES
Numerous studies have been carried out to examine the detailed tissue and cellular distribution of each SPC (Day et al. 1992 , Schafer et al. 1993 , Beaubien et al. 1995 , Dong et al. 1995 , 1997 , Seidel et al. 1998 . Table 1 summarizes the overall distribution profile. In general, it can be stated that cells or cell lines do not express only one SPC at a time, but rather express a distinct 'cocktail' of SPCs. Overlapping cellular expression of SPCs raises the question of possible redundancy of processing. This is best illustrated by studies carried out in the rat brain, which examined SPC mRNA distribution by in situ hybridization (Fig. 4) . Analysis of the brain localization shows that SPCs have distinct distribution patterns, suggesting that they also have distinct functions. However, overlapping regional expressions are also observed, which hints at some redundant functions in the brain.
A summary of the analysis of the cellular distribution of SPCs in the rat brain is given in Table 2 . In situ hybridization studies of brain tissue at a cellular level are very useful when illustrated in this way, as they show that some SPCs (SPC2, SPC3 and SPC6) are exclusively expressed in neurons, whereas others (SPC1, SPC4 and SPC7) are expressed in both neurons and glial cells. In contrast to glial cells, which possess only a constitutive secretory pathway, neurons also have a regulated secretory pathway. These data suggest an association of SPC2, SPC3 and SPC6 with the neuroendocrine phenotype and specialized functions within the regulated secretory pathway.
Of the seven known mammalian SPCs, the distribution of SPC5 is the most restricted, as it is not expressed elsewhere than in testicular germ cells (Nakayama et al. 1992 , Seidah et al. 1992 . Although this unique expression pattern may reflect a highly specialized processing function, no SPC substrates have, as yet, been identified in germ cells. The exclusive expression of SPC5 in germ cells also suggests unique transcriptional regulation of this gene. However, the germ cells also have the capacity to express other SPCs, including SPC1 and SPC7. A comparative in situ hybridization analysis of adjacent sections of rat seminiferous tubules (Fig. 5 ) reveals that both SPC5 and SPC7 are expressed within germ cells, but in a mutually exclusive pattern, some tubules containing greater levels of SPC5 mRNA, the others being rich in SPC7. These patterns of expression suggest distinct roles of SPC5 and SPC7 in the different stages of germ cell maturation.
The extensive tissue distribution studies carried out on the SPCs have revealed that each SPC could have a distinct function in vivo, as no two SPCs have identical patterns. These patterns of expression (whether at a cellular or intracellular level) could compensate for some apparent common cleavage specificities observed in vitro. A substrate cleaved by an SPC in vitro may in fact never encounter that SPC in vivo, because they either are not co-expressed in the same cell or are simply sorted to different intracellular compartments. Thus overlapping functions of SPCs in vivo may in fact be et al. 1997) , the processing of pro-glucagon, pro-somatostatin, and pro-insulin in the pancreatic islets was shown to be severely impaired. However, in the case of pro-insulin processing, a severe but incomplete block in processing was observed, suggesting that other convertases are able to provide some compensatory cleavage at SPC2-favored sites in pro-insulin. In SPC2-null mice, pancreatic concentrations of insulin are still detectable, but represent only about 20% of normal insulin concentrations. Thus, whereas some substrates are in fact cleaved by more than one SPC (at the same cleavage site), it appears that in vivo compensatory mechanisms are mostly limited events.
BIOLOGICAL FUNCTIONS OF SPC ENZYMES
A major objective of investigations on SPCs has been to determine the specific biological functions of each enzyme -that is, to establish specific target substrates within their biological context. Many studies have focused on the use of cellular co-infections using Vaccinia virus recombinants (Thomas et al. 1988) to establish the cleavage properties of SPCs on target substrates. This approach has been useful in certain applications, for example in the rapid production of recombinant (Thomas et al. 1988 , Benjannet et al. 1991 , Leduc et al. 1992 . However, this method has its drawbacks, such as degradation of the cellular environment induced by vaccinia infection and the difficulty of carrying out comparative kinetic studies of substrate cleavage. Taken together, these conditions may explain certain ambiguities that have been observed with the use of co-infection, as for example in the cleavage of pro-glucagon by SPC2. In this case, the Vaccinia virus approach was unable to demonstrate the specific formation of glucagon by SPC2 (even in the presence of 7B2) (Dhanvantari et al. 1996) , whereas SPC2 antisense studies, gene knockout and gene transfection studies (Rouille et al. 1994 , 1997a , Furuta et al. 1997 all showed the obvious involvement of SPC2 in the formation of glucagon. Thus only a partial assessment of SPC biological function is possible with co-expression or in vitro studies. To complete the elucidation of the biological role of SPCs, complementary in vivo approaches must be considered, such as the study of naturally occuring mutants (e.g. the LoVo cell line) and SPC gene modulation using antisense (or gene knockout) technologies. Another interesting method by which to investigate the role of SPCs in vivo is to study the co-localization of the enzymes with their substrates at the tissue, cellular and intracellular level. An example of such an approach is illustrated in Fig. 6 , showing the co-localization of POMC mRNA with various SPC mRNAs in hypothalamic neurons. The data show that all POMC neurons contain SPC2 and SPC3, that some POMC neurons  5. Comparative distribution of SPC5 and SPC7 mRNAs by in situ hybridization in adjacent sections of rat testis. In the top panels, note the complementary distributions, which show seminiferous tubules with high levels of SPC7 (open arrows) or high levels of SPC5 (white arrows). In the bottom panels, numbers indicate identical seminiferous tubles in adjacent tissue sections. Tubules 1-5 express high levels of SPC7, whereas tubules 6-9 express high levels of SPC5.
  and others · SPCs: molecular specificity to therapeutic applicationscontain SPC4, but that none can be shown to express SPC6. These data reflect the established role of SPC2 and SPC3 on in vivo POMC processing, but also suggest that SPC4 could also play a role in POMC processing in a subset of arcuate neurons. This type of co-localization approach is a powerful way to gather data on cellular enzyme-substrate relationships and potential SPC biological functions.
One of the SPCs with the best-defined biological function is SPC1 (Denault & Leduc 1996 , Nakayama 1997 , Molloy et al. 1999 . In terms of cell metabolism, SPC1 is believed to be vital, as it is considered to be a 'housekeeping' convertase, processing constitutively secreted proteins in all cells. Its ubiquitous distribution, cellular localization and substrate specificity support this notion. In vitro and in vivo studies reveal that SPC1 is able to cleave various constitutively secreted protein precursors, including insulin pro-receptor (Mondino et al. 1991) , pro-von Willebrand factor (Wise et al. 1990 ), pro--nerve growth factor (Bresnahan et al. 1990 ), pro-transforming growth factor 1 (Dubois et al. 1995) and pro-endothelin-1 (Denault et al. 1995a ). SPC1 does not appear to be essential for survival in established cell lines, as the absence of active SPC1 in LoVo or CHO RPE.40 cells is not lethal. Survival of these cells without functional SPC1 may be due to the expression of other SPCs, such as SPC4, in LoVo cells, suggesting compensatory functions by other SPCs. However, the essential role of SPC1 has been revealed by in vivo studies demonstrating that SPC1 expression is essential for the normal development of the mouse embryo (Roebroek et al. 1998) .
Whereas SPC1 is ubiquitously expressed, other SPCs, such as SPC2 and SPC3, have well-defined patterns of expression that are mostly restricted to the neuroendocrine system. This distribution is consistent with their accepted role in pro-hormone and pro-neuropeptide processing. Furthermore, SPC2 and SPC3 are co-localized with peptide hormones within dense-core secretory granules. The specific role of SPC2 and SPC3 has been shown in the processing of pro-insulin (Bennett et al. 1992 , Smeekens et al. 1992 , pro-glucagon (Rouille et al. , 1997a and POMC (Benjannet et al. 1991 , Thomas et al. 1991 . These cleavage specificity studies have been supported by gene knockout (Furuta et al. 1998 ) and antisense studies (Bloomquist et al. 1991 , Rouille et al. 1994 , Rothenberg et al. 1996 , Johanning et al. 1998 . These substrates possess multiple basic residues that are differentially cleaved by SPC2 and SPC3, yielding different products depending on the relative expression of SPC2 and SPC3. In general, it appears that SPC3 activity results in a more limited precursor proteolysis, generating relatively high-molecular-weight species, whereas SPC2 cleavage is more extensive, producing smaller forms of mature products.
The issue of differential processing by SPC2 and SPC3 can be exemplified with pro-dynorphin as a model precursor. The interest in pro-dynorphin lies in the fact that it contains multiple apparently similar paired basic amino acid cleavage sites, in addition to two potential single Arg cleavage sites. Pro-dynorphin is also, along with POMC and pro-enkephalin, one of three precursors involved in the production of mammalian opioid peptides. In vivo, differential processing of this 26 kDa pro-protein is observed in different tissues (Day & Akil 1989) . For example, pro-dynorphin is expressed in anterior pituitary gonadotropes and in magnocellular neurons of the hypothalmus. In the anterior pituitary, pro-dynorphin is processed to yield high-molecular intermediates of 8, 10 and 16 kDa, whereas, in the hypothalamus, final opioid peptide products, including dynorphin A(1-17,) dynorphin A(1-8), dynorphin B(1-13) and -neoendorphin, are obtained (Fig. 7) . In vitro studies demonstrated that SPC3 is primarily responsible for the production of the high-molecular-weight intermediates. The 8 kDa intermediate requires cleavage at a single Arg residue, a function that can be carried out by SPC3 (Dupuy et al. 1994) . In contrast, SPC2 was shown to generate the smaller opioid-active dynorphin A(1-17), dynorphin B(1-13), and -neo-endorphin products (Day et al. 1998) . In common with SPC3, SPC2 was also able to cleave at single Arg residues, generating the C-peptide but, in addition, dynorphin A(1-8). The differential cleavage patterns of pro-dynorphin by SPC2 and SPC3 obtained in vitro reflect the processing patterns observed in vivo. Colocalization studies indicate that hypothalamic magnocellular neurons express both SPC2 and SPC3, whereas anterior lobe gonadotropes express only SPC3. Thus complete processing of prodynorphin to biologically active opioid peptide products is dependent upon the expression of SPC2. Additional support comes from studies with SPC2-null mice, which showed impaired prodynorphin processing, especially in the formation of dynorphin A(1-8) (Day et al. 1998) .
Compared with SPC1, SPC2 and SPC3, the other members of the SPC family have been the object of fewer studies and, thus, their biological roles are not as well defined. The first enzymatic studies on SPC4 activity revealed characteristics similar to those of SPC1, but with some differences in specificity (Rehemtulla et al. 1993) . On the basis of preliminary studies on tissue distribution and enzymatic properties, SPC4 was first believed to be very similar to SPC1. Moreover, the close proximity of the SPC1 and SPC4 genes on chromosome 15 suggested that these genes evolved from a common ancestor by gene duplication (Kiefer et al. 1991) . However, more recent studies on SPC1 and SPC4 in vitro activities have highlighted the differences between these enzymes. Compared with SPC1, SPC4 has a low sensitivity for calcium chelators and dithiothreitol (Mains et al. 1997) , and it is not affected by the SPC1 inhibitor, 1-antitrypsin-portland (AT-PDX, see below). In fact, several reports show that SPC4 is closer to SPC6 than SPC1 in many respects. SPC6 is the enzyme with the greatest degree of sequence homology with SPC4 (Lusson et al. 1993 , Nakagawa et al. 1993 . In vitro enzymatic studies of the recombinant enzymes revealed a close relationship between SPC4 and SPC6 (Creemers et al. 1993a ). Finally, a distinct distribution has been observed for the two enzymes, which is complementary in some tissues (Dong et al. 1995 , Zheng et al. 1997 . Despite the differences in the in vitro properties of SPC1 and SPC4, all the reported SPC4 substrates can also be cleaved by SPC1 or other SPCs with an equal or superior efficiency. Among the reported SPC4 substrates are pro-brain-derived neurotrophic factor, proneurotrophin 3 (Seidah et al. 1996a) , the insulin receptor (Alarcon et al. 1994) , pro-nerve growth factor (Seidah et al. 1996b ), pro-somatostatin (Brakch et al. 1995 , human serum albumin (Mori et al. 1999 ) and the HIV viral coat protein, GP160 (Hallenberger et al. 1992 , Morikawa et al. 1993 .
The cleavage of the GP160 precursor illustrates the need to confirm in vitro data with in vivo observations. Even though enzymatic assays with recombinant proteins suggest that GP160 is cleavable by SPC1 and SPC4 (Decroly et al. 1994 ), this processing is probably not physiologically relevant, because it occurs with very low efficiency (Inocencio et al. 1997) . Moreover, SPC1-deficient cell lines process GP160 as efficiently as do normal cells (Ohnishi et al. 1994) . Finally, it has been proposed that a Ca 2+ -independent protease may in fact be responsible for in vivo GP160 cleavage (Inocencio et al. 1997) . The role of SPC4 in vivo remains unclear, as none of the above cited precursors demonstrates a clear preferential susceptibility to SPC4 activity.
The cloning of SPC6 cDNA revealed the existence of two enzyme isoforms, named SPC6-A and SPC6-B, which differ only in their C-terminal end. These isoforms are believed to exert different functions, as SPC6-A has a soluble C-terminal domain and is targeted towards the dense-core secretory granules in endocrine cells, whereas SPC6-B has a transmembrane C-terminal domain and is located in the vesicles of the Golgi apparatus (De Bie et al. 1996) . The SPC6 isoforms are differentially expressed in the gastrointestinal tract,  7. Differential processing of pro-dynorphin by SPC2 and SPC3. Cleavage by SPC3 produces large intermediate molecules, whereas SPC2 generates smaller peptides. The processing pattern obtained with SPC3 corresponds to that observed in vivo within the anterior lobe gonadotropes. The processing pattern obtained with SPC2 corresponds to that observed in vivo within the hypothalamus (see text for discussion). NE, -neo-endorphin; Dyn, dynorphin. and the expression of SPC6-A is affected by dietary content (Udupi et al. 1997) , suggesting a regulatory role for the processing of gut peptides. Other potential biological functions of SPC6 have been identified. It may play a role in the cleavage of pro-neurotensin/neuromedin N in human colon cancer cells (Rovere et al. 1998) . It may be also involved in the process of sexual differentiation, by activating pro-Müllerian substance (Nachtigal & Ingraham 1996) . In addition, the transfection of SPC6 in COS cells induces cleavage of the extracellular domains of the receptor protein tyrosine phosphatases (Campan et al. 1996) .
Enzymatic characterization of the recombinant SPC7 reveals a substrate specificity largely similar to that of SPC1 (Munzer et al. 1997) , with which it is highly homologous. Just like SPC1, SPC7 has a C-terminal transmembrane domain and a cytoplasmic tail responsible for its subcellular localization at the TGN level, possibly with an endosomal recycling pathway similar to that of SPC1. At the structural level, PC7 has a C-terminal region rich in serine and threonine, whereas SPC1 has a cysteine-rich domain. Interestingly, SPC7 is not phosphorylated like SPC1, but is palmitoylated in its cytoplasmic tail (van de Loo et al. 1997) . As this enzyme was only recently discovered, more studies are needed to determine its role in vivo.
CLINICAL ASPECTS OF SPC ACTIVITY
Theoretically, there are two ways of designing therapeutic approaches targeting SPCs: restoring the defective processing responsible for a disorder, and blocking a processing event that is essential for a given disease state.
With regard to the restoration of defective processing, there is, at present, little evidence of pathologies associated with altered protein processing. Some autosomal dominant syndromes have been identified in which a mutated precursor leads to an incorrect processing pattern, inducing pathological conditions. These diseases are related to the impaired processing of pro-insulin (Peters 1987 ), pro-albumin (Brennan 1989 , and blood coagulation factor IX (Bentley et al. 1986 ). However, these diseases are not related to an impaired activity of SPCs, but are caused by structural modifications in the substrate. One interesting application of SPCs in the restoration of hormone production is the re-engineering of rat prepro-insulin-1 to introduce SPC1 cleavage sites, thus allowing processing into mature insulin by SPC1 in liver (Muzzin et al. 1997) .
The first evidence of a metabolic disorder induced by a defective enzyme involving precursor cleavage came from the study of fat/fat mice. A spontaneous mutation in the CPE gene of this strain induced a single amino acid substitution in a highly conserved domain of the exopeptidase, yielding an inactive enzyme. Biochemical analysis of insulinlike peptides in these animals revealed a high content (approximately 80%) of unprocessed proinsulin, whereas the processed insulin chains still had their C-terminal pairs of basic residues untrimmed. However, an unexpected finding was the detection of unprocessed pro-insulin. This phenomenon may be explained by the observation that SPC2 activity is inhibited by C-terminally extended peptides, possibly by a product inhibition mechanism (Day et al. 1998) .
Recently, an isolated case of SPC3 deficiency has been identified in a human patient. One allele of the SPC3 gene has a Gly<Arg483 mutation that prevents processing of pro-SPC3 and leads to its retention in the ER. The mutation of the other allele causes skipping of exon 5, leading to loss of 26 residues, a frameshift and creation of a premature stop codon within the catalytic domain (Jackson et al. 1997) . These mutations seem to produce effects similar to those observed in the fat/fat phenotypethat is, obesity and pro-insulinemia, accompanied by abnormal glucose homeostasis, hypogonadotropic hypogonadism and hypocortisolism. Such inherited syndromes of normal proteolytic processing are uncommon; they arise from the occasional combination of two alleles containing random mutations of an SPC gene. Recent advances in gene transfer therapy (Knoell & Yiu 1998) raise the hope that these rare inherited defects could be corrected by the reintroduction of normal SPC genes.
The other field of therapeutic application involving SPC activity is the inhibition of unwanted proteolytic processing. Various pathogenic agents, including bacterial toxins and viral coat proteins, have been found to require proteolytic processing by SPCs in order to produce their effects (Garten et al. 1994 , Gordon et al. 1995 , Rott et al. 1995 . Blocking the proteolytic processing of such pathogenic proteins opens the way to the development of new therapeutic treatments based on enzyme inhibition.
Blocking SPC activity may be deleterious, as these enzymes are essential for the normal expression of important cellular proteins. Thus, for each disease state, the enzyme specificity of pathogenic precursors must be well understood and the design of therapeutic SPC inhibitors should be made as specific as possible, in order to avoid cross-inhibition of important cellular proteolytic processing. Nonetheless, it cannot be ruled out that, in certain pathological states, wide-spectrum SPC inhibitors may also be useful.
SPC INHIBITION
Ideally, effective control of the production of biological peptides involved in various disease states could be achieved by specifically inhibiting the enzymatic activity of SPCs. Although antisense technologies aimed at decreasing the endogenous levels of SPC mRNA have been considered, enzyme-based inhibition achieved by designing a variety of molecular entities, ranging from non-peptidic or peptidomimetic molecules to small peptide substrates and to larger proteins, would be the preferred choice.
The initial characterization of the enzymatic specificities of SPCs spearheaded efforts in the design, conception and testing of compounds aimed at inhibiting these enzymes. A straightforward approach has made use of the consensus cleavage site sequence of SPCs for the synthesis of peptides capable of acting as pseudosubstrates or transition state analogues. For example, elucidation of the SPC1 recognition sequence, Arg-Xaa-Xaa-Arg, has led to the design of molecules such as the family of chloromethylketones, which behave as tightbinding irreversible inhibitors of SPC1 (Angliker 1995 , Jean et al. 1995 .
Structure-activity studies using peptidyl substrates based on a region spanning the pro-region and catalytic domain of mouse SPC3 , Basak et al. 1995 or the cleavage sequence of human pro-parathyroid hormone (Lazure et al. 1998) , showed that inhibition constants in the micromolar range can be attained. Some of the peptidomimetic agents irreversibly react with the activesite serine, thus acting as suicide inhibitors. These peptide-based molecules have proven quite useful in ascertaining the role of SPCs in processing precursors of viral glycoproteins (Hallenberger et al. 1992 , Volchkov et al. 1998 , hormones (Lazure et al. 1998) , enzymes and other pro-proteins (Denault et al. 1995b , Jean et al. 1993 , Ledgerwood et al. 1996 . They have the inherent advantage of being synthesized on a large scale and having the propensity of modified peptides to penetrate membranes, making them well suited for therapeutic use as largespectrum, pharmacologically stable inhibitors. However, none of them has, as yet, demonstrated marked specificity. It is clear that, because of the enzymatic property of this family of proteinases of cleaving on the C-terminal of basic residues, other considerations will have to be taken into account in order to synthesize compounds of higher specificity. One of these is the availability of all SPCs, enabling researchers to compare the inhibitory properties of a given molecule in vitro. The use of these isolated SPCs for the identification of specific SPC inhibitors with high throughput methods such as peptide combinatorial libraries is already under way, as in the case of SPC2 and SPC3 (Apletalina et al. 1998) .
Because most enzymes possess natural inhibitors, efforts have also been made to identify endogenous molecules that could modulate SPC activity. As discussed above, one of these, the dual function 7B2 that facilitates pro-SPC2 maturation (Muller et al. 1997) , has also been found to be inhibitory. Indeed, within its C-terminal peptide, the Lys171-Lys172 site is particularly important for the ability of 7B2 to inhibit SPC2 (van Horssen et al. 1995) . Pro-segments of SPCs can also be considered to be modulators of enzymatic activity. Acting as a multifunctional domain, the pro-peptide not only acts as a steric chaperone, but also binds to catalytic domains of SPCs and inhibits protease activity. This mechanism has been observed in vitro and in vivo for SPC1 and SPC3, whereby pro-segments inhibit the enzymes by a slow, tight-binding mechanism (Boudreault et al. 1998) . In fact, the pro-domains are quite potent inhibitors, as demonstrated for SPC1, with IC 50 values of 14 nM.
Serpins (SERine Protease INhibitors) are naturally occuring proteins that play a role in the regulation of serine proteases activity. Although most serpins identified today specifically inhibit trypsin-like serine proteases, a recently described member of this family, called PI8, has been shown to inhibit SPC1 by a rapid, tight-binding mechanism (Dahlen et al. 1998) . PI8 is a 45 kDa ovalbumin-type serpin that contains two SPC1 recognition sequences, Arg-Asn-Ser-Arg339 and Arg339-Cys-Lys-Arg342 in its reactive site loop. Once this loop enters the catalytic pocket, it forms an SDS-stable serpin-enzyme complex, characteristic of physiological serpin-proteinase interactions.
Attempts at abolishing SPC activity that were based on redesigning the reactive site of known inhibitors of serine proteinases to fit SPC recognition sequences were initially performed using turkey ovomucoid third domain. Its reactive site was re-engineered by incorporating the SPC1 cleavage site, Arg-Xaa-Lys-Arg, in its reactive pocket, yielding a molecule of K a 1·1 10 7 M 1 (Lu et al. 1993) . Similar modifications of the bait region of the general protease inhibitor, 2 macroglobulin (Gly-Phe-Tyr-Glu686-Ser-Asp< Arg-Ser-Lys-Arg686-Ser-Leu), also led to the production of an intracellularly active SPC1 inhibitor (Van Rompaey et al. 1997) .
Using a similar approach of site-directed mutagenesis of reactive centers, other existing polypeptides of the serpin family were targeted that led to the development of a potent inhibitor for SPC1. Indeed, changing residues corresponding to the P4 and P1 residues of the reactive site loop of 1-antitrypsin to accommodate the specificity of SPC1 (Ala-Ile-Pro-Met<Arg-Ile-Pro-Arg) led to a molecule specifically inhibiting SPC1, with an IC 50 of 0·6 nM . Interestingly, this serpin, AT-PDX, conserves the biochemical properties of the native serpin, by rapidly forming an irreversible complex with SPC1 that is resistant to heat and denaturants. Kinetic analysis of AT-PDX inhibition has revealed that it acts through a slow, tight-binding mechanism. It also behaves as a suicide substrate inhibitor, as binding to the active site results in an equal probability that proteolysis will ensue or that a kinetically trapped SDS-stable complex with the enzyme will be formed (Dufour et al. 1998 . Because of its high selectivity toward SPC1 , this novel inhibitor has already been used to assess the biological role of SPC1 in processing different precursors , Denault et al. 1995b , Watanabe et al. 1995 , Decroly et al. 1996 , Kayo et al. 1997 , Zarkik et al. 1997 , Abrami et al. 1998 , Cui et al. 1998 , Logeat et al. 1998 . Other naturally occuring substances have been tested for their ability to inhibit SPCs. A recent study reported the identification of substances (andrographolides) from the medicinal plant, Andrographis paniculata, that possess low (>30 µM) inhibitory potencies toward SPCs (Basak et al. 1999) . Lately, much focus has been put on developing approaches to abolishing SPC1-mediated cleavage of viral and bacterial pathogens. However, because not all these precursors are processed in the same cellular compartment, the physicochemical properties of the inhibitory compounds must be considered. For example, it is believed that cleavage of the protective antigen of Anthrax is performed by SPC1 found at the cell surface, that proteolysis of exotoxin A of Pseudomonas would take place in endosomal compartments, but that viral glycoprotein precursors such as the Ebola glycoprotein would occur in the TGN. This signifies that inhibiting cell surface, and possibly endosomal, SPC1 may be facilitated by its accessibility to hydrophilic molecules such as peptides and proteins. To reach the intracellular TGN, more lipophilic compounds would be needed. These issues must also be considered for all other SPCs.
CONCLUSIONS
The mammalian SPCs comprise a complex family of enzymes that carry out apparently similar processing functions (cleavage at basic residues), yet clearly have unique biological roles as a result of their distinct catalytic specificities and localizations. Although the clinical relevance of SPCs remains unclear, the design of specific inhibitors will undoubtedly lead to a better understanding of the complex cellular mechanisms in which the SPCs participate. A better understanding of the substrate specificity of each SPC could lead to a rational design of specific inhibitors. These substratespecificity studies must be focused on a more relevant biological context than has been done previously. Although the design of specific SPC inhibitors is a major goal, targeting a single SPC with a highly specific inhibitor may not have the fully desired effect, because of some partial compensatory mechanisms, thus the development of wide-spectrum inhibitors may also be useful under certain conditions. However, as several SPCs are often co-expressed within a particular cell type, this approach may prove to be particularly risky. The knowledge of how these enzymes function and interact is critical for the future successful application of SPC inhibitors within a therapeutic context.
